Difference between revisions of "Part:BBa K1391101:Design"
(→Design Notes) |
|||
| (2 intermediate revisions by the same user not shown) | |||
| Line 9: | Line 9: | ||
Gantenerumab has shown therapeutic potential in recent clinical trials. Human Ig-M can be anchored to the membrane to interact with the b-cell receptor (BCR) complex. Human antibody membrane localization tag is natively found in human, membrane-bound antibodies. | Gantenerumab has shown therapeutic potential in recent clinical trials. Human Ig-M can be anchored to the membrane to interact with the b-cell receptor (BCR) complex. Human antibody membrane localization tag is natively found in human, membrane-bound antibodies. | ||
| + | This gene is expressed under a hEF1a promoter for constitutive high level expression in mammalian cells. It adheres to RFC 65 for mammalian parts. | ||
| + | This part was created using a single pot LR reaction. The promoter is flanked by B4 and P1 sites and the gene is flanked by P1 and B2 sites. Either of these can be extracted using a BP reaction. This part adheres to RFC 65 for recombination based cloning of mammalian parts. | ||
| + | (Ignore the RFC 65 link it is an automated link that links to a page unrelated to the iGEM RFC 65) | ||
===Source=== | ===Source=== | ||
Latest revision as of 16:14, 30 October 2014
pEXPR_Gantenerumab Variable Human Ig-M Light Chain
- 10INCOMPATIBLE WITH RFC[10]Illegal PstI site found at 532
- 12INCOMPATIBLE WITH RFC[12]Illegal PstI site found at 532
- 21COMPATIBLE WITH RFC[21]
- 23INCOMPATIBLE WITH RFC[23]Illegal PstI site found at 532
- 25INCOMPATIBLE WITH RFC[25]Illegal PstI site found at 532
Illegal AgeI site found at 64 - 1000COMPATIBLE WITH RFC[1000]
Design Notes
Gantenerumab has shown therapeutic potential in recent clinical trials. Human Ig-M can be anchored to the membrane to interact with the b-cell receptor (BCR) complex. Human antibody membrane localization tag is natively found in human, membrane-bound antibodies.
This gene is expressed under a hEF1a promoter for constitutive high level expression in mammalian cells. It adheres to RFC 65 for mammalian parts.
This part was created using a single pot LR reaction. The promoter is flanked by B4 and P1 sites and the gene is flanked by P1 and B2 sites. Either of these can be extracted using a BP reaction. This part adheres to RFC 65 for recombination based cloning of mammalian parts.
(Ignore the RFC 65 link it is an automated link that links to a page unrelated to the iGEM RFC 65)
Source
Fusion protein of 3 human peptide sequences